Captrust Financial Advisors Boosts Holdings in ResMed Inc. (NYSE:RMD)

Captrust Financial Advisors increased its holdings in ResMed Inc. (NYSE:RMD - Free Report) by 901.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 48,537 shares of the medical equipment provider's stock after acquiring an additional 43,689 shares during the period. Captrust Financial Advisors' holdings in ResMed were worth $11,849,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in RMD. Janus Henderson Group PLC raised its holdings in shares of ResMed by 4.8% in the first quarter. Janus Henderson Group PLC now owns 19,516 shares of the medical equipment provider's stock valued at $3,865,000 after purchasing an additional 902 shares during the last quarter. Cetera Advisors LLC purchased a new position in shares of ResMed in the 1st quarter worth approximately $257,000. GAMMA Investing LLC grew its holdings in shares of ResMed by 56.1% in the second quarter. GAMMA Investing LLC now owns 1,324 shares of the medical equipment provider's stock valued at $253,000 after acquiring an additional 476 shares in the last quarter. DNB Asset Management AS increased its position in shares of ResMed by 4.1% during the second quarter. DNB Asset Management AS now owns 24,049 shares of the medical equipment provider's stock valued at $4,603,000 after acquiring an additional 938 shares during the last quarter. Finally, Versant Capital Management Inc lifted its holdings in ResMed by 196.7% during the second quarter. Versant Capital Management Inc now owns 181 shares of the medical equipment provider's stock worth $35,000 after acquiring an additional 120 shares during the period. Institutional investors own 54.98% of the company's stock.

ResMed Stock Performance

Shares of NYSE:RMD traded down $4.19 during midday trading on Monday, reaching $244.83. 575,940 shares of the company traded hands, compared to its average volume of 1,033,826. The firm's fifty day moving average price is $242.21 and its two-hundred day moving average price is $225.87. The firm has a market capitalization of $35.94 billion, a price-to-earnings ratio of 32.43, a price-to-earnings-growth ratio of 1.81 and a beta of 0.69. The company has a quick ratio of 1.91, a current ratio of 2.92 and a debt-to-equity ratio of 0.13. ResMed Inc. has a 12 month low of $159.60 and a 12 month high of $260.49.

ResMed (NYSE:RMD - Get Free Report) last announced its quarterly earnings results on Thursday, October 24th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.03 by $0.17. The firm had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.19 billion. ResMed had a net margin of 23.15% and a return on equity of 25.53%. The company's revenue for the quarter was up 11.1% on a year-over-year basis. During the same period in the prior year, the firm posted $1.64 earnings per share. On average, equities analysts expect that ResMed Inc. will post 9.28 earnings per share for the current year.

ResMed Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 12th. Stockholders of record on Thursday, November 7th will be given a dividend of $0.53 per share. The ex-dividend date is Thursday, November 7th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 0.87%. ResMed's dividend payout ratio (DPR) is currently 28.08%.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Bank of America upped their price objective on ResMed from $240.00 to $270.00 and gave the company a "buy" rating in a research note on Thursday, September 26th. Robert W. Baird raised their price objective on shares of ResMed from $280.00 to $283.00 and gave the stock an "outperform" rating in a report on Friday, October 25th. Baird R W raised shares of ResMed to a "strong-buy" rating in a research report on Tuesday, September 24th. Wolfe Research reissued an "underperform" rating and set a $180.00 target price on shares of ResMed in a research report on Wednesday, September 18th. Finally, Royal Bank of Canada lifted their price target on shares of ResMed from $224.00 to $232.00 and gave the stock a "sector perform" rating in a report on Friday, October 25th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, ResMed currently has an average rating of "Moderate Buy" and a consensus price target of $225.70.

Insider Transactions at ResMed

In related news, insider Justin Leong sold 6,160 shares of the firm's stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $243.09, for a total value of $1,497,434.40. Following the sale, the insider now directly owns 21,718 shares of the company's stock, valued at $5,279,428.62. This trade represents a 22.10 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Witte Jan De sold 796 shares of the business's stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $248.81, for a total transaction of $198,052.76. Following the completion of the transaction, the director now directly owns 6,723 shares of the company's stock, valued at approximately $1,672,749.63. This represents a 10.59 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 68,408 shares of company stock valued at $16,398,132. 0.71% of the stock is currently owned by company insiders.

ResMed Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.